FIP1L1 and Chronic Eosinophilic Leukemia, Not Otherwise Specified: A study conducted by Klion et al. involved gradually reducing the imatinib dosage for five CEL patients with the FIP1L1-PDGFRα fusion gene from 300-400mg daily to 100mg daily.